<body><div><figure><img src="https://img.particlenews.com/image.php?type=thumbnail_580x000&amp;url=0a4mgy_0qxQcNrt00" alt="https://img.particlenews.com/image.php?url=0a4mgy_0qxQcNrt00" width="1536" height="1024" ><figcaption>phototechno</figcaption></figure><ul><li>Canadian specialty pharmaceutical company Knight Therapeutics (<a href="https://seekingalpha.com/symbol/KHTRF?hasComeFromMpArticle=false&amp;source=content_type%253Areact%257Csection%253Amain_content%257Cbutton%253Abody_link%257Cfirst_level_url%253Anews">OTCPK:KHTRF</a>) announced Thursday a licensing agreement with Amneal Pharmaceuticals (NASDAQ:<a href="https://seekingalpha.com/symbol/AMRX?hasComeFromMpArticle=false&amp;source=content_type%253Areact%257Csection%253Amain_content%257Cbutton%253Abody_link%257Cfirst_level_url%253Anews">AMRX</a>) to obtain exclusive rights to Parkinson’s disease therapy IPX203 in Canada and Latin America.</li><li>Per the terms, Montreal-based Knight (<a href="https://seekingalpha.com/symbol/KHTRF?hasComeFromMpArticle=false&amp;source=content_type%253Areact%257Csection%253Amain_content%257Cbutton%253Abody_link%257Cfirst_level_url%253Anews">OTCPK:KHTRF</a>) will receive regional </li></ul></div></body>

Mountain View, CA

NewsBreak

Amneal Pharma inks licensing pact with Knight Therapeutics

Canadian specialty pharmaceutical company Knight Therapeutics (OTCPK:KHTRF) announced Thursday a licensing agreement with Amneal Pharmaceuticals (NASDAQ:AMRX) to obtain exclusive rights to Parkinson’s disease therapy IPX203 in Canada and Latin America. Per the terms, Montreal-based Knight (OTCPK:KHTRF) will receive regional.